Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Shares Outstanding (Diluted Average) (2019 - 2025)

Sangamo Therapeutics (SGMO) has 7 years of Shares Outstanding (Diluted Average) data on record, last reported at $304.3 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 53.01% year-over-year to $304.3 million; the TTM value through Sep 2025 reached $304.3 million, up 53.01%, while the annual FY2024 figure was $201.7 million, 15.62% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $304.3 million in Q3 2025 per SGMO's latest filing, up from $257.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $304.3 million in Q3 2025 and bottomed at $143.1 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $180.6 million, with a median of $171.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 2.17% in 2022, then soared 53.01% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $144.6 million in 2021, then grew by 6.76% to $154.3 million in 2022, then grew by 13.02% to $174.4 million in 2023, then rose by 15.62% to $201.7 million in 2024, then skyrocketed by 50.85% to $304.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $304.3 million in Q3 2025, $257.0 million in Q2 2025, and $220.3 million in Q1 2025.